Search Browse Earnings

Aclaris Therapeutics, Inc. — SlamSEC

Aclaris Therapeutics, Inc.

Nasdaq:ACRS

Pharmaceutical Preparations·WAYNE, PA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$18.7M

-40.1% YoY

FY 2025

Adj. EBITDA

-$141.1M

-753.9% margin

FY 2025

Net Income

-$132.1M

-705.5% margin

FY 2025

EPS (Diluted)

-$1.71

FY 2025

Stock Price

$3.51

+14.7%

2026-03-10

52W Range

$1.05 – $4.89

P/E Ratio

-2.1x

Market Cap

$423.3M

Cash

$24.6M

FY 2025

Total Debt

$10.7M

FY 2021

Net Cash

$13.9M

FY 2021

Enterprise Value

$409.4M

Debt / EBITDA

0.1x

FY 2025

EV / EBITDA

-2.9x

Employees

—